media – Page 33 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies

PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP manufacturing, aiming to accelerate non-viral cell and gene therapies for the benefit of patients. PlasmidFactory GmbH, a leading European CDMO for plasmid and Minicircle DNA, brings more than 25 years of experience and over 3,500 DNA constructs delivered worldwide. The Fraunhofer IZI contributes extensive translational capabilities in immuno-oncology, regenerative medicine, and advanced cell manufacturing. Together, they are accelerating the development of next-generation, virus-free genetic engineering platforms while maintaining the highest quality and regulatory standards. In the past, the two partners have already successfully established new manufacturing processes for CAR-T cells at Fraunhofer IZI and conducted joint research projects on virus-free gene transfer, which served as the foundation for the production of clinical cell products. By building on our long-standing collaboration, this partnership ...
- Source: drugdu
- 99
- October 9, 2025
More Patients Using GLP-1 Drugs Prior To Weight-Loss Surgery

By Dennis Thompson HealthDay ReporterWEDNESDAY, Oct. 8, 2025 (HealthDay News) — Many more folks fighting excess weight are using weight-loss drugs like Ozempic or Zepbound to cut pounds before undergoing bariatric surgery, a new study says. The use of these drugs before surgery rose 16-fold among patients preparing for weight-loss surgery, researchers reported Sunday at the American College of Surgeons’ annual meeting in Chicago. “While patients previously believed they had to choose between GLP-1 receptor agonists and surgery, we’re now seeing that people are using both,” said lead researcher Dr. Stefanie Rohde, a general surgery resident at the Ohio State University Wexner Medical Center in Columbus. “We know that patients can use GLP-1s after bariatric surgery to amplify their weight loss,” Rohde said in a news release. “But all of this is still very new in terms of how to manage patients effectively.” For the study, researchers looked at the ...
- Source: drugdu
- 124
- October 9, 2025
CanSino accelerates global deployment of dual vaccines

CanSino’s independently developed 13-valent pneumococcal polysaccharide conjugate vaccine PCV13i and Asia’s first quadrivalent meningococcal polysaccharide conjugate vaccine MCV4 were shipped to the domestic and overseas markets respectively. CanSino Biologics’ independently developed 13-valent pneumococcal polysaccharide conjugate vaccine, Upexin®, was officially approved by the National Medical Products Administration in June of this year. It is China’s first pneumococcal polysaccharide conjugate vaccine to utilize a dual vector consisting of an avirulent mutant of diphtheria toxin (CRM197) and tetanus toxoid (TT). This vaccine provides enhanced protection against the four serotypes (19F, 19A, 7F, and 3) that carry the heaviest burden of pneumococcal disease in children in China. It is reported that by 2026, Upexin® will expand its reach into the domestic market, with overseas expansion also in the works. When Youpexin® was shipped domestically, Asia’s first ACYW135 group meningococcal polysaccharide conjugate vaccine (CRM197 vector) Manhaixin® also departed from Tianjin and was sent to Indonesia. ...
- Source: drugdu
- 122
- October 9, 2025
Subsidiary’s chorionic follicle-stimulating hormone αN02 injection approved for marketing in China

Changchun High-techChangchun High-Tech Industry (Group) Co., Ltd. (hereinafter referred to as ” Changchun High-Tech “) issued an announcement stating that its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”) recently received the “Drug Registration Certificate” approved and issued by the State Food and Drug Administration. Its application for the choriofollicle-stimulating hormone αN02 injection has been approved for marketing in China. The approved indication is for use in combination with a gonadotropin-releasing hormone antagonist for controlled ovarian stimulation to induce the development of multiple follicles. A single subcutaneous injection of choriofollicle-stimulating hormone αN02 injection (Jinsaijia®) replaces the 7-day use of follicle-stimulating hormone for assisted reproduction .Ovarian stimulation therapy brings new options. In recent years, demand for assisted reproductive technology has continued to grow. In 2015, Jinsai Pharmaceutical launched the first domestically developed recombinant human follicle-stimulating hormone (RFH) for injection (Jinsai Heng®). This short-acting formulation, administered daily, was ...
- Source: drugdu
- 129
- October 9, 2025
Pfizer and the U.S. government reached a drug pricing agreement to bring U.S. drug prices in line with other developed countries

After the U.S. stock market opened on Tuesday, Pfizer,　　which has been deeply affected by the uncertainty of U.S. pharmaceutical policies this year,The company’s stock price rose by over 4% at one point. Multiple sources indicate that Pfizer CEO Albert Bourla will visit the White House later on Tuesday to announce drug pricing policies and a $70 billion domestic investment plan with Trump. ( Pfizer daily chart, Source: TradingView) In addition to Pfizer, many large pharmaceutical companies also rose .Bristol-Myers Squibb rose nearly 3%.Up 2%, AmgenUp 1%. If the news is true, Pfizer has resolved at least two policy uncertainties : US President Trump once wrote to Pfizer and 16 other pharmaceutical companies asking for price cuts, and demanded that prices in the United States should not be more expensive than those in developed countries such as Europe (the “most favored nation” policy); Trump also announced tariffs on branded drugs last ...
- Source: drugdu
- 117
- October 9, 2025
Another pharmaceutical giant terminates AAV gene therapy business

According to foreign media reports, Biogen has terminated all gene therapy projects based on adeno-associated virus (AAV) capsids. In fact, Biogen deprioritized gene therapy as early as 2023. Now, as part of its ongoing capital allocation strategy, the company will completely abandon AAV technology. Biogen is a biotechnology company with deep expertise in rare and genetic diseases. The company said it will continue to focus on this area in the future and concentrate its resources on advanced therapies and drugs that have greater potential and are more likely to bring better therapeutic effects to patients. Most of the team members who were previously responsible for AAV vector research and development have been reassigned to other positions within the company, but a small number of people are still facing layoffs, involving R&D, operations, technology and other positions. Biogen is not the first company to abandon AAV technology. AAV (adeno-associated virus) is ...
- Source: drugdu
- 137
- October 9, 2025
Signed a licensing agreement with Glenmark Specialty for the Ruikang trastuzumab project, with revenue potentially exceeding US$1.1 billion.

Hengrui Medicine recently announced the signing of a licensing agreement with Glenmark Specialty SA for the Ruikang Trastuzumab project. The agreement provides for a paid license to Glenmark Specialty SA for the company’s innovative Class 1 drug, Ruikang Trastuzumab (SHR-A1811), for which the company holds independent intellectual property rights. Ruikang Trastuzumab is an antibody-drug conjugate (ADC) independently developed by Hengrui that targets HER2. It binds to and is internalized by HER2-expressing tumor cells. Within the tumor cell lysosome, trastuzumab releases a toxin through proteolytic cleavage, inducing cell cycle arrest and ultimately apoptosis. The released toxin is highly permeable, exerting a bystander effect and further enhancing anti-tumor efficacy. The company’s Ruikang Trastuzumab was approved for marketing in China in May 2025. It is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received ...
- Source: drugdu
- 146
- October 9, 2025
Maghreb Pharma Expo

Organiser: Easy Fairs Time：April 21, 2026 – April 23, 2026 address：Palais des expositions Pins Maritimes Alger 16000, Algiers, Algeria Exhibition hall：Safex Expo Center Product range: Medical Products Section: Medical diagnostic equipment and supplies, electronic medical equipment and instruments, rescue equipment, medical reagents and devices, etc. Hospital Supplies Section: Catheters, interventional materials, surgical hygiene products, disposable medical consumables, surgical instruments, medical clothing and bedding, emergency equipment, maternal and child care equipment, sterilization equipment, etc. Laboratory Equipment Section: Laboratory instruments and equipment, optical instruments and equipment, image analysis and processing systems, testing instruments and devices, laboratory renovation and upgrading technologies, consumables, and related software, etc. Pharmaceuticals Section: Various new and specialty drugs, traditional Chinese medicines, Western medicines, Chinese herbal health products, nutritional foods, etc.; traditional medicines, Chinese herbs, herbal remedies, etc. Pharmaceutical Equipment Section: Pharmaceutical production equipment and technologies, pharmaceutical packaging equipment, pharmaceutical packaging materials, pharmaceutical production, cleaning, and sterilization systems. ...
- Source: drugdu
- 113
- October 9, 2025
The application for marketing authorization of trivalent influenza virus split vaccine has been accepted

People’s Finance News reported on September 24 that Kangtai Biological(300601) announced on September 24 that the influenza vaccine developed by the companyThe application for marketing authorization of the viral split vaccine recently received an acceptance notice issued by the National Medical Products Administration. The influenza virus split vaccine 　　whose marketing authorization application was accepted this time is a trivalent influenza vaccine. Together with the quadrivalent influenza virus split vaccine that the company has applied for production registration, the quadrivalent influenza virus split vaccine (for people aged 6-35 months) that has been approved for clinical trials, the quadrivalent influenza virus split vaccine (MDCK cells) and the trivalent influenza virus split vaccine (MDCK cells), they constitute an influenza vaccine series covering all age groups. https://finance.eastmoney.com/a/202509243522587919.html
- Source: drugdu
- 94
- October 8, 2025
Walvax Biopharma’s vaccine receives Jordanian Drug Registration Certificate, marking a key step forward in its Middle East market expansion.

　　Shanghai Securities News China SecuritiesNet News (Reporter Sun Zhong) Walvax BioAn announcement on the 29th stated that the 13-valent pneumococcal polysaccharide conjugate vaccine produced by its subsidiary Yuxi Walvax recently received a “Drug Registration Certificate” issued by the Jordan Food and Drug Administration. 　　The Yuxi Walvax 13-valent pneumococcal polysaccharide conjugate vaccine is mainly suitable for vaccination of infants and children aged 6 weeks to 5 years (before the age of 6 years). It is used to prevent infectious diseases caused by the 13 serotypes of pneumococcus contained in this vaccine (type 1, type 3, type 4, type 5, type 6A, type 6B, type 7F, type 9V, type 14, type 18C, type 19A, type 19F and type 23F). The vaccine was approved for sale in China in 2020. 　　Currently, pneumococcal infection remains one of the leading causes of death in children under five worldwide. In Jordan, this infection also poses a ...
- Source: drugdu
- 111
- October 8, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.